C WorldWide Group Holding A S increased its position in Celgene Co. (NASDAQ:CELG) by 3.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 126,797 shares of the biopharmaceutical company’s stock after purchasing an additional 3,727 shares during the quarter. C WorldWide Group Holding A S’s holdings in Celgene were worth $11,347,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in CELG. Johnson Financial Group Inc. lifted its holdings in Celgene by 4.5% during the second quarter. Johnson Financial Group Inc. now owns 13,100 shares of the biopharmaceutical company’s stock worth $1,040,000 after buying an additional 567 shares during the period. Wetherby Asset Management Inc. lifted its holdings in Celgene by 5.4% during the second quarter. Wetherby Asset Management Inc. now owns 11,857 shares of the biopharmaceutical company’s stock worth $942,000 after buying an additional 603 shares during the period. Tompkins Financial Corp lifted its holdings in Celgene by 3.8% during the second quarter. Tompkins Financial Corp now owns 18,059 shares of the biopharmaceutical company’s stock worth $1,434,000 after buying an additional 656 shares during the period. Hills Bank & Trust Co. lifted its holdings in Celgene by 4.9% during the third quarter. Hills Bank & Trust Co. now owns 14,255 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 672 shares during the period. Finally, Coastline Trust Co lifted its holdings in shares of Celgene by 14.5% during the 2nd quarter. Coastline Trust Co now owns 5,370 shares of the biopharmaceutical company’s stock valued at $427,000 after purchasing an additional 680 shares during the last quarter. 73.58% of the stock is currently owned by institutional investors.
Several analysts have recently commented on CELG shares. BidaskClub lowered Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Zacks Investment Research lowered Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. Mizuho set a $117.00 price objective on Celgene and gave the company a “buy” rating in a report on Tuesday, October 30th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 25th. Finally, Cantor Fitzgerald started coverage on Celgene in a report on Monday, October 1st. They set an “overweight” rating and a $100.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $117.91.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. Analysts forecast that Celgene Co. will post 7.45 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2018/11/09/celgene-co-celg-shares-bought-by-c-worldwide-group-holding-a-s.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What is a Swap?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.